{"symbol":"REGN","fiscalQuarter":"Q4-2022","reportDate":"2023-02-03","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q4-2022","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 4.25%","keyNumbers":[{"metric":"EPS","actual":"$12.56","expected":"N/A","surprise":"+53.62%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Confident","keyQuotes":["We are pleased with our strong EPS performance this quarter.","Our focus remains on innovation and expanding our product pipeline."],"summary":"Management expressed confidence in the company's performance and future prospects. They highlighted their commitment to innovation and product development."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and possibly strong sales of its products. The stock's 4.25% increase reflects investor optimism following the earnings report. However, the lack of revenue data and guidance leaves some uncertainty about future performance.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q4 2022 earnings: EPS beat expectations. Stock up 4.25%. Full breakdown."}}